scholarly journals An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management

2020 ◽  
Vol 48-49 ◽  
pp. 101691
Author(s):  
Padraic Smith ◽  
Anita Lavery ◽  
Richard C. Turkington
Keyword(s):  
Side Effects ◽  
Cancer Therapy ◽  
Anti Cancer ◽  
Gastrointestinal Side Effects

Gastrin, Nitric Oxide Synthase and their Role in Ulceration and Distention of Stomach after Cisplatin and Taxol Treatment

1997 ◽  
Vol 3 (S2) ◽  
pp. 85-86
Author(s):  
Ying Wang ◽  
Surinder K. Aggarwal
Keyword(s):  
Side Effects ◽  
Chemotherapeutic Agent ◽  
Severe Nausea ◽  
Smooth Muscle Contractility ◽  
Anti Cancer ◽  
Gastrointestinal Side Effects ◽  
Cancer Agent ◽  
Oxide Synthase ◽  
Head Neck

Cisplatin, a potent broad spectrum anti-cancer agent, has been proven effective in the treatment of different kinds of cancer, such as bladder, lung, ovarian, head, neck, etc.. Drawbacks of this chemotherapeutic drug are its toxic side-effects, which include severe nausea, vomiting, stomach distention and peptic ulcer.Taxol is another effective chemotherapeutic agent which is usually used in conjection with cisplatin. It has demonstrated impressive activity in breast, ovarian, lung, and head and neck cancers. The toxic side-effects include nausea, vomiting, nephrotoxicity. The mechanism of these gastrointestinal side-effects are still unclear. Because of the role of NOS and gastrin on stomach smooth muscle contractility and gastroprotection, these were studied in the rats after cisplatin and taxol administration.Wistar rats(100-150 g) were injected with cisplatin(9 mg/kg) and taxol(20 mg/kg) in five divided dosages over a period of 5 days. Rats were killed one day after the last injection. Rat stomach tissues were fixed in Bouin’s solution and processed for light microscopy.

A tumor-sensitive biological metal–organic complex for drug delivery and cancer therapy

2020 ◽  
Vol 8 (32) ◽  
pp. 7189-7196 ◽  
Author(s):  
Zelei Jiang ◽  
Tong Wang ◽  
Shuai Yuan ◽  
Mengfan Wang ◽  
Wei Qi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Cancer Drug ◽  
Organic Complex ◽  
Anti Cancer ◽  
Metal Organic Complex ◽  
Metal Organic ◽  
Inhibition Of Tumor Growth

Tumor-sensitive bioMOC-Zn(Cys) was developed using an endogenous Zn2+ ion and l-cystine for the delivery of anti-cancer drug DOX. In vivo application of DOX@bioMOC-Zn(Cys) shows the increased inhibition of tumor growth and prevented side effects.

scholarly journals Anti-cancer properties of ruthenium compounds: NAMI-A and KP1019

2020 ◽  
Vol 74 ◽  
pp. 12-19
Author(s):  
Michał Juszczak ◽  
Magdalena Kluska ◽  
Daniel Wysokiński ◽  
Katarzyna Woźniak
Keyword(s):  
Cancer Research ◽  
Side Effects ◽  
Cancer Therapy ◽  
Treatment Strategies ◽  
Therapeutic Strategies ◽  
Current Data ◽  
Chemical Agents ◽  
Ruthenium Compounds ◽  
Anti Cancer ◽  
Tumor Origin

Cancer research is among the key challenges in current medicine and biology. Many decades of investigations have brought measurable benefits in both areas with regard to expanding the knowledge of the molecular mechanism of cancer and developing treatment strategies. Despite that cancers are still among diseases with the highest mortality rate, and cancer treatment is often unsuccessful and connected with severe side effects. The development of therapeutic strategies in both targeting the primary tumor origin and preventing metastasis is largely based on testing newly synthesized chemical agents, including a group of metal-containing complexes. It seems that ruthenium-containing complexes are of high potential in cancer therapy, and our work presents the current data about the application of ruthenium-based complexes − NAMI-A and KP1019 in cancer therapy.

Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade

2020 ◽  
Vol 27 ◽  
Author(s):  
Muhammad Sohail ◽  
Wenna Guo ◽  
Zhiyong Li ◽  
Hui Xu ◽  
Feng Zhao ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Research Progress ◽  
Cancer Drug ◽  
Conventional Chemotherapy ◽  
Anti Cancer ◽  
Cancer Drug Delivery

: In recent years, due to the shortcomings of conventional chemotherapy, such as poor bioavailability, low treatment index and unclear side effects, the focus of cancer research has shifted to new nanocarriers of chemotherapeutic drugs. By using biodegradable materials, nanocarriers generally have the advantages of good biocompatibility, low side effects, targeting, controlled release profile, and improved efficacy. And more to the point, nanocarrier based anti-cancer drug delivery systems clearly show the potential to overcome the problems associated with conventional chemotherapy. In order to promote the deepening of research and development in this field, we herein summarized and analyzed various nanocarrier based drug delivery systems for cancer therapy, including the concepts, types, characteristics and preparation methods. The active and passive targeting mechanisms of cancer therapy were also included, along with a brief introduction of the research progress of nanocarriers used for anti-cancer drug delivery in the past decade.

scholarly journals Cancer Therapy by Silver Nanoparticles: Fiction or Reality?

2022 ◽  
Vol 23 (2) ◽  
pp. 839
Author(s):  
Dávid Kovács ◽  
Nóra Igaz ◽  
Mohana K. Gopisetty ◽  
Mónika Kiricsi
Keyword(s):  
Silver Nanoparticles ◽  
Side Effects ◽  
Cancer Therapy ◽  
Silver Nanoparticle ◽  
Cancer Biology ◽  
New Class ◽  
Specific Targeting ◽  
Clinical Utilization ◽  
Therapeutic Concepts ◽  
Anti Cancer

As an emerging new class, metal nanoparticles and especially silver nanoparticles hold great potential in the field of cancer biology. Due to cancer-specific targeting, the consequently attenuated side-effects and the massive anti-cancer features render nanoparticle therapeutics desirable platforms for clinically relevant drug development. In this review, we highlight those characteristics of silver nanoparticle-based therapeutic concepts that are unique, exploitable, and achievable, as well as those that represent the critical hurdle in their advancement to clinical utilization. The collection of findings presented here will describe the features that distinguish silver nanoparticles from other anti-cancer agents and display the realistic opportunities and implications in oncotherapeutic innovations to find out whether cancer therapy by silver nanoparticles is fiction or reality.

Sulfinpyrazone or Acetylsalicylic Acid to Prevent Postoperative Thrombus Formation in Arteriovenous Fistulas of Haemodialysis Patients

1979 ◽  
Author(s):  
F Albert ◽  
U Schmidt
Keyword(s):  
Side Effects ◽  
Acetylsalicylic Acid ◽  
Thrombus Formation ◽  
Significant Inhibition ◽  
High Rate ◽  
Controlled Clinical Trial ◽  
Arteriovenous Fistulas ◽  
Arteriovenous Shunts ◽  
Gastrointestinal Side Effects ◽  
Antithrombotic Efficacy

The effect of sulfinpyrazone (200 mg three times a day) and acetylsalicylic acid (500 mg three times a day) on the incidence of thrombosis of arteriovenous shunts was investigated in a controlled clinical trial. In 36 patients with chronic renal failure scheduled to begin haemodialysis the same operating team constructed a subcutaneous fistula in the distal forearm. During the first six weeks after the operation the antithrombotic efficacy proved to be good for both substances. No differences of thrombotic events between the two treatment groups were statistically significant. But in contrast to acetylsalicylic acid sulfinpyrazone made no significant inhibition of platelet - aggregation; sulfinpyrazone probably will prevent the clot formation by prolonging the shortened platelet survival in uraemic patients. In a high rate of patients given acetylsalicylic acid (10 out of 17) there were local bleeding and gastrointestinal side effects. In consequence we should prefer sulfinpyrazone, because in the sulfinpyrazone group side effects were minimal and in none patient withdrawal from the study was necessitated.

Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy

2020 ◽  
Vol 27 (13) ◽  
pp. 2118-2132 ◽  
Author(s):  
Aysegul Hanikoglu ◽  
Hakan Ozben ◽  
Ferhat Hanikoglu ◽  
Tomris Ozben
Keyword(s):  
Oxidative Stress ◽  
Drug Resistance ◽  
Side Effects ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Anticancer Drugs ◽  
Chemotherapeutic Agents ◽  
Oxidation Reactions ◽  
Hybrid Compounds ◽  
Induced Apoptosis

: Elevated Reactive Oxygen Species (ROS) generated by the conventional cancer therapies and the endogenous production of ROS have been observed in various types of cancers. In contrast to the harmful effects of oxidative stress in different pathologies other than cancer, ROS can speed anti-tumorigenic signaling and cause apoptosis of tumor cells via oxidative stress as demonstrated in several studies. The primary actions of antioxidants in cells are to provide a redox balance between reduction-oxidation reactions. Antioxidants in tumor cells can scavenge excess ROS, causing resistance to ROS induced apoptosis. Various chemotherapeutic drugs, in their clinical use, have evoked drug resistance and serious side effects. Consequently, drugs having single-targets are not able to provide an effective cancer therapy. Recently, developed hybrid anticancer drugs promise great therapeutic advantages due to their capacity to overcome the limitations encountered with conventional chemotherapeutic agents. Hybrid compounds have advantages in comparison to the single cancer drugs which have usually low solubility, adverse side effects, and drug resistance. This review addresses two important treatments strategies in cancer therapy: oxidative stress induced apoptosis and hybrid anticancer drugs.

Sign in / Sign up

Export Citation Format

Share Document